ENDRA Life Sciences Inc. (NDRA)

Over the past six months, ENDRA Life Sciences, Inc. stock price has been impacted by several events. On November 17, 2025, the company recapped major milestones and announced its Third Quarter 2025 financial results, which coincided with a -7.46% stock movement. On November 20, 2025, positive results from a feasibility study demonstrating TAEUS Liver's ability to accurately quantify liver fat fraction were announced, followed by a -15.19% stock movement. On December 4, 2025, additional feasibility results showed strong concordance between TAEUS Liver and MRI-PDFF, associated with a -7.67% stock movement. On February 26, 2026, favorable results from a new study demonstrated the TAEUS device's robust intra-user repeatability and inter-user reproducibility, leading to a +2.89% stock movement. On March 25, 2026, ENDRA Life Sciences initiated a review of strategic alternatives, which saw an +8.38% increase in stock price. On March 31, 2026, the company reported its Fourth Quarter and Full Year 2025 financial results and flagged "going-concern risk" and announced a pivot to a digital asset treasury, also reporting sharply cutting 2025 operating costs. On April 21, 2026, an 8-K filing indicated that an equity shortfall put ENDRA Life Sciences at renewed Nasdaq delisting risk. As of May 1, 2026, the share price was $4.97, representing a decline of 20.48% over the past year.

Based on the available information, there is no explicit mention or indication of demand seasonality for ENDRA Life Sciences, Inc.'s products and services. Demand for its TAEUS platform is likely driven by ongoing medical needs, clinical trial schedules, and regulatory approvals rather than seasonal consumer patterns.

ENDRA Life Sciences, Inc. is a pre-commercial medical technology company based in Ann Arbor, Michigan, founded in 2007, operating in the Healthcare sector. It focuses on developing its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS®) platform to enhance clinical diagnostic ultrasound by assessing tissue fat content and monitoring tissue ablation. The TAEUS platform primarily measures fat in the liver to assess and monitor steatotic liver disease (SLD), also known as metabolic dysfunction-associated steatohepatitis (MASH) or non-alcoholic fatty liver disease (NAFLD). ENDRA envisions TAEUS as a biomarker solution for metabolic disease management, targeting pharmaceutical companies, clinical research organizations and other healthcare providers. The company currently generates no commercial revenue and is working towards regulatory clearance for its TAEUS platform, with a planned subscription-based revenue model post-commercialization.

ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan, United States. The company's TAEUS technology is designed to work with existing ultrasound systems globally, impacting "one million ultrasound systems in global use today," but specific details about its direct operational geographic footprint or market penetration beyond the United States were not explicitly detailed.

ENDRA Life Sciences' brand reputation has been influenced by both positive clinical advancements and significant financial and operational challenges. The company has reported strong clinical progress with its TAEUS Liver device, demonstrating accuracy in quantifying liver fat fraction and strong concordance with MRI-PDFF. However, ENDRA has faced significant financial and operational hurdles, including continued operating losses, a review of strategic alternatives, flagging "going-concern risk," and renewed Nasdaq delisting risk, which have negatively impacted its reputation.

ENDRA Life Sciences Inc. has a mix of institutional and individual ownership. As of April 8, 2026, there were 7 institutional owners and shareholders holding a total of 71,825 shares, including Altium Capital Management LP, The Vanguard Group Inc., and Morgan Stanley. Public companies and retail investors hold the largest share at 93.59%, followed by other institutional investors at 4.75%, and mutual funds & ETFs at 1.67%. Individual insiders hold 5.72% and institutions hold 6.41%. Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 120.7%.